DDInter1407 DDInter1676
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Peginterferon alfa-2a {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam